Another Roche TIGIT disappointment
Skyscraper-07 fails, while a Poseida-originated Car-T is also scrapped.
Skyscraper-07 fails, while a Poseida-originated Car-T is also scrapped.
The group expects to raise nearly $170m.
Merck & Co gives up on Agenus, while Sanofi hands BND-22 back to Biond.
Meanwhile, Tango tries again in PRMT5.
The company takes its T-cell engager into the clinic, just as Roche and Sanofi exit.
Felmetatug vedotin’s exit could be bad news for Mersana.
Meanwhile, Olema’s KAT6 inhibitor will take on rival projects from Pfizer and Menarini.
While Cogent joins the FGFR party.